A dangerous drug-resistant fungus that has been rapidly spreading in European hospitals has now reached the UK. The Candidozyma auris virus, which was originally confined to a few isolated cases, has now become prevalent on every continent except Antarctica.
The UK has experienced a concerning rise in confirmed cases of C. auris. Between November 2024 and April 2025, there were 134 recorded cases, marking a 23% increase compared to the previous six months.
C. auris, a yeast species, typically poses minor issues for healthy individuals but can be fatal for those with compromised immune systems, especially if it enters the bloodstream or infects vital organs.
Despite initially being discovered in Japan in 2009, C. auris has since been identified in over 40 countries. The fungus can spread through direct contact with contaminated surfaces or infected individuals.
The adhesive properties of C. auris make it challenging to eliminate from surfaces, allowing it to persist for extended periods. Its elusive nature also contributes to its rapid spread, as individuals can harbor the virus on their skin without showing symptoms, unknowingly transmitting it within hospitals.
In severe cases, C. auris infections can manifest in various ways, affecting body parts such as the blood, brain, bones, abdomen, and respiratory tract. Additionally, the virus’s ability to induce resistance to multiple medications, including strains resistant to all available treatments, poses a significant threat.
Medical professionals may struggle to identify C. auris accurately, as standard laboratory tests can misdiagnose it as more common yeasts. The UK Health Security Agency (UKHSA) has underscored the escalating global health risks associated with C. auris, emphasizing the importance of stringent infection prevention measures and ongoing research to curb its spread in healthcare settings.